Beijing Hospital

Running trials

• Not yet recruiting

  An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis

  NCT07818291· Phase 1· Shanghai Lanyi Therapeutics Co., Ltd.· Source

• Recruiting

  Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes

  NCT07580638· Chipscreen Biosciences, Ltd.· Source

• Recruiting

  Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

  NCT07776522· Phase 2· West China Hospital· Source

• Recruiting

  Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction

  NCT07693049· Peking University Third Hospital· Source

• Not yet recruiting

  Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

  NCT07741045· Phase 3· Hangzhou PhecdaMed Co., Ltd.· Source

• Recruiting

  A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

  NCT07684157· Phase 2· Jacobio Pharmaceuticals Co., Ltd.· Source

• Enrolling by invitation

  Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

  NCT07658417· Novo Nordisk A/S· Source

• Recruiting

  Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

  NCT07444372· Beijing Anzhen Hospital· Source

• Recruiting

  Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

  NCT07477626· Phase 3· Sun Yat-sen University· Source

• Recruiting

  5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease

  NCT07781579· Beijing Hospital· Source

• Recruiting

  A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

  NCT07339267· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

  NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source

• Recruiting

  A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

  NCT07249632· Phase 3· RemeGen Co., Ltd.· Source

• Enrolling by invitation

  Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT

  NCT07690306· Xiangya Hospital of Central South University· Source

• Not yet recruiting

  A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

  NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Active, not recruiting

  A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

  NCT07245407· AstraZeneca· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

  NCT07156500· Phase 3· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

  NCT07135141· Beijing Friendship Hospital· Source

• Active, not recruiting

  ASKC200 for Knee Osteoarthritis Pain

  NCT07742852· Phase 2· Jiangsu Aosaikang Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

  NCT07136792· Guangdong Provincial People's Hospital· Source

• Recruiting

  A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

  NCT06974851· Phase 3· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  QA108 Phase III Study in Subjects With Intermediate AMD

  NCT07189169· Phase 3· Smilebiotek Zhuhai Limited· Source

• Recruiting

  Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

  NCT07185841· Phase 1/2· Fujian Haixi Pharmaceuticals Co., Ltd.· Source

• Not yet recruiting

  The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

  NCT07028632· Phase 2· iRegene Therapeutics Co., Ltd.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

  NCT06969807· Phase 2· Chinese PLA General Hospital· Source

• Active, not recruiting

  A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

  NCT06884293· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Recruiting

  A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

  NCT06346600· Skyline Therapeutics· Source

• Not yet recruiting

  A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

  NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Not yet recruiting

  Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

  NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Active, not recruiting

  Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes Mellitus

  NCT06587438· Sinocare· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Active, not recruiting

  A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

  NCT06666855· Phase 3· Santen Pharmaceutical Co., Ltd.· Source

• Recruiting

  Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)

  NCT06880575· Beijing Hospital· Source

• Recruiting

  Longitudinal Cohort of Thrombosis and Hemostasis Diseases

  NCT06727669· Peking University People's Hospital· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Vor Biopharma· Source

• Not yet recruiting

  Henagliflozin's Impact on Prediabetes Remission

  NCT06448130· Phase 4· Shandong Provincial Hospital· Source

• Recruiting

  Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules

  NCT07773064· Beijing Hospital· Source

• Recruiting

  Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT06521255· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Recruiting

  Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods

  NCT06314295· Beijing Hospital· Source

• Recruiting

  ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

  NCT06321081· Phase 2· Beijing Hospital· Source

• Recruiting

  Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

  NCT05986864· Phase 1/2· Skyline Therapeutics (US) Inc.· Source

• Recruiting

  Myasthenia Gravis Registry in China

  NCT06241521· Huashan Hospital· Source

• Recruiting

  The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

  NCT06167681· Phase 1/2· iRegene Therapeutics Co., Ltd.· Source

• Recruiting

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

  NCT05979051· Phase 2/3· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

Showing 50 of 83.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration7 recruiting
• Prostate cancer6 recruiting
• Myasthenia gravis4 recruiting
• Type 2 diabetes4 recruiting
• Coronary artery disease3 recruiting
• Heart failure3 recruiting
• Obesity3 recruiting
• Parkinson disease3 recruiting
• Alzheimer disease2 recruiting
• Chronic kidney disease2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lung cancer2 recruiting
• Obstructive sleep apnoea2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Haemophilia1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoporosis1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101

  NCT06545162· Phase 1· Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

  NCT06596876· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  Bactiseal Catheter Safety Registry Study

  NCT06276543· Integra LifeSciences Corporation· Source

• Completed

  A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

  NCT06589765· Phase 3· Shandong Suncadia Medicine Co., Ltd.· Source

• Completed

  A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

  NCT06581627· Phase 1· Novo Nordisk A/S· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Withdrawn

  Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

  NCT06176235· Phase 2· Peking University People's Hospital· Source

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

  NCT06739044· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

  NCT06041217· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

  NCT05945927· Hoffmann-La Roche· Source

• Completed

  A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

  NCT05971940· Phase 3· Eli Lilly and Company· Source

• Completed

  A SAD Study of ZT002 Injection in Healthy Participants

  NCT06423872· Phase 1· Beijing QL Biopharmaceutical Co.,Ltd· Source

• Completed

  A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

  NCT05658484· Phase 4· Biogen· Source

• Completed

  Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations

  NCT06614153· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

  NCT05417841· Beijing Hospital· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

  NCT05691712· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

  NCT05679258· Phase 1· Shanghai Henlius Biotech· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

  NCT05520177· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Ipsen· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

  NCT05438875· Phase 3· Peking University People's Hospital· Source

• Completed

  Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

  NCT05439629· Phase 3· Bio-Thera Solutions· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

  NCT05352516· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

  NCT05379829· Phase 1· Novo Nordisk A/S· Source

• Completed

  Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

  NCT05267054· Phase 1/2· BeiGene· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Chinese Osteoporotic Fracture Registration Network Platform

  NCT05339425· Peking Union Medical College Hospital· Source

• Completed

  A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

  NCT05083923· Phase 3· Biogen· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

  NCT04944706· Phase 2· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

  NCT05359068· Phase 3· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Completed

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· Phase 3· Bayer· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04005716· Phase 3· BeiGene· Source

• Completed

  Methotrexate in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis

  NCT03815448· Zhujiang Hospital· Source

• Completed

  Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

  NCT04085276· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Terminated

  A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

  NCT03330418· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Macular degeneration12 works · 10 trials
• Peripheral artery disease9 works · 0 trials
• Multiple system atrophy6 works · 1 trial
• IgA nephropathy6 works · 1 trial